Use of coronary computed tomographic angiography to guide management of patients with coronary disease by Williams, Michelle C. et al.
Listen to this manuscript’s
audio summary by
JACC Editor-in-Chief
Dr. Valentin Fuster.
J O U R N A L O F T H E AM E R I C A N C O L L E G E O F C A R D I O L O G Y V O L . 6 7 , N O . 1 5 , 2 0 1 6
ª 2 0 1 6 B Y T H E AM E R I C A N C O L L E G E O F C A R D I O L O G Y F O UN DA T I O N I S S N 0 7 3 5 - 1 0 9 7 / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R h t t p : / / d x . d o i . o r g / 1 0 . 1 0 1 6 / j . j a c c . 2 0 1 6 . 0 2 . 0 2 6ORIGINAL INVESTIGATIONSUse of Coronary Computed Tomographic
Angiography to Guide Management of
Patients With Coronary Disease
Michelle C. Williams, MD,a Amanda Hunter, MD,a Anoop S.V. Shah, MD,a Valentina Assi, PHD,b
Stephanie Lewis, PHD,b Joel Smith, PHD,c Colin Berry, MD,d Nicholas A. Boon, MD,a Elizabeth Clark,a
Marcus Flather, MD,e John Forbes, PHD,f Scott McLean, PHD,g Giles Roditi, MD,d Edwin J.R. van Beek, MD,a
Adam D. Timmis, MD,h David E. Newby, MD,a on behalf of the SCOT-HEART InvestigatorsABSTRACTFro
bC
Ce
Gla
Ins
Re
of
Lo
mu
(EdBACKGROUND In a prospective, multicenter, randomized controlled trial, 4,146 patients were randomized to receive
standard care or standard care plus coronary computed tomography angiography (CCTA).
OBJECTIVES The purpose of this study was to explore the consequences of CCTA-assisted diagnosis on invasive
coronary angiography, preventive treatments, and clinical outcomes.
METHODS In post hoc analyses, we assessed changes in invasive coronary angiography, preventive treatments, and
clinical outcomes using national electronic health records.
RESULTS Despite similar overall rates (409 vs. 401; p ¼ 0.451), invasive angiography was less likely to demonstrate
normal coronary arteries (20 vs. 56; hazard ratios [HRs]: 0.39 [95% confidence interval (CI): 0.23 to 0.68];
p < 0.001) but more likely to show obstructive coronary artery disease (283 vs. 230; HR: 1.29 [95% CI: 1.08 to 1.55];
p ¼ 0.005) in those allocated to CCTA. More preventive therapies (283 vs. 74; HR: 4.03 [95% CI: 3.12 to 5.20];
p < 0.001) were initiated after CCTA, with each drug commencing at a median of 48 to 52 days after clinic atten-
dance. From the median time for preventive therapy initiation (50 days), fatal and nonfatal myocardial infarction was
halved in patients allocated to CCTA compared with those assigned to standard care (17 vs. 34; HR: 0.50 [95% CI:
0.28 to 0.88]; p ¼ 0.020). Cumulative 6-month costs were slightly higher with CCTA: difference $462 (95% CI: $303
to $621).
CONCLUSIONS In patients with suspected angina due to coronary heart disease, CCTA leads to more appropriate
use of invasive angiography and alterations in preventive therapies that were associated with a halving of fatal and
non-fatal myocardial infarction. (Scottish COmputed Tomography of the HEART Trial [SCOT-HEART]; NCT01149590)
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1760P atients who present with chest painof suspected cardiac origin requireaccurate and timely diagnosis to
guide the implementation of appropriate
investigations and therapeutic interventions.
Current U.S. (1) and European (2) guidelines
describe a range of potential noninvasive
imaging modalities to investigate patientswith suspected stable angina pectoris due to coronary
heart disease. However, there is little definitive or
consistent evidence of superiority of 1 imaging modal-
ity over another, and none has yet demonstrated
improvements in downstream clinical outcomes
attributable to better diagnostic performance. More-
over, American guidelines (1) specifically favor stress
testing as the initial diagnostic test of choice and
reserve coronary computed tomography angiography
(CCTA) for patients who are unable to undergo stress
testing.SEE PAGE 1769The SCOT-HEART (Scottish COmputed Tomography
of theHEART) trial showed that, when used in addition
to standard care, CCTA markedly clarified the diag-
nosis for patients with suspected angina due to coro-
nary heart disease (3). This diagnostic improvement
was associated with alterations in downstream in-
vestigations and treatments and with potential im-
provements in clinical outcome. However, whether
CCTA-guided changes in diagnosis led to appropriate
improvements in invasive coronary angiography and
initiation of preventive treatments, andwhether these
changes could be attributable to an improvement in
clinical outcome, has not been explored.
It would be neither practical nor ethical to under-
take invasive coronary angiography in all patients
within a large trial of a noninvasive diagnostic test for
angina pectoris due to coronary heart disease. How-
ever, a reasonable proxy for the assessment of diag-
nostic accuracy is to compare the rates of normal
coronary arteries or obstructive coronary arteryrd. The Clinical Research Facility Glasgow and Clinical Research F
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To assess the appropriateness of therapy would again
be inferential and requires the assessment of im-
provements in clinical outcomes directly attributable
to coronary heart disease. For these clinical im-
provements to occur, the changes in management
consequent on the diagnostic test have to be imple-
mented and temporally associated with any observed
benefits. Clearly, it is not sufficient for the test to be
merely performed.
In this study, we aimed to assess the diagnostic
utility of CCTA against the findings at invasive coro-
nary angiography, and to investigate the timing and
therapeutic implementation of CCTA-guided changes
in preventive treatment. Finally, we explored the
beneficial effects of these investigative and therapeu-
tic implementations on coronary heart disease events.
METHODS
STUDY DESIGN. The SCOT-HEART study was a pro-
spective, open-label, parallel group, multicenter,
randomized controlled trial that assessed the role of
CCTA in patients with suspected angina due to coro-
nary heart disease who attended a cardiology clinic.
The study design has previously been described in
detail (4) and the primary study findings published
(3). The study was conducted in accordance with the
Declaration of Helsinki and with research ethics
committee approval.
PARTICIPANTS. Participants were recruited from
dedicated cardiology chest pain clinics where they
were referred with suspected angina due to coronary
heart disease. A total of 4,146 patients age 18 to 75
years were recruited as described previously (4).
Participants were randomized 1:1 to standard care or
standard care plus $64-slice CCTA using a web-based
randomization system with minimization for age, sex,
body mass index, diabetes, history of coronary heart
disease, atrial fibrillation, and the baseline diagnosis
of angina due to coronary heart disease. Standard ofacility Tayside are supported by NRS. Drs. Williams
undation. Dr. Shah has received speaker fees from
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1761care included stress testing according to established
local clinical protocols.
COMPUTED TOMOGRAPHY CORONARY ANGIOGRAPHY.
Participants in the CCTA arm of the study underwent
coronary artery calcium scoring and CCTA using
64-detector (Brilliance 64, Philips Healthcare, North
Andover, Massachusetts; or Biograph mCT, Siemens,
Erlangen, Germany) or 320-detector (Aquilion One,
Toshiba Medical Systems, Tochigi, Japan) row scan-
ners at 1 of 3 imaging sites. Computed tomography
images were assessed by $2 trained observers (4)
with excellent reproducibility (5). The overall results
of the scan were defined as normal (<10% luminal
cross-sectional area), nonobstructive (mild 10% to
49%, moderate 50% to 70%), or obstructive (>70%)
coronary artery disease. Overall, obstructive coronary
artery disease was defined as a cross-sectional
luminal stenosis of >70% in $1 major epicardial
vessel or >50% in the left main stem.
INVASIVE CORONARY ANGIOGRAPHY AND CORONARY
REVASCULARIZATION. The Scottish national elec-
tronic health record system was used to obtain
information on the timing and results of subsequent
invasive coronary angiography and coronary revas-
cularization (percutaneous coronary intervention or
coronary artery bypass graft surgery). All procedures
were performed according to routine clinical
practice by the attending clinicians, interventional
cardiologists, and surgeons. The results of invasive
coronary angiograms were categorized as normal,
nonobstructive coronary artery disease, or obstruc-
tive coronary artery disease. Obstructive coronary
artery disease was classified as a lesion with >50%
diameter stenosis and/or abnormal fractional flow
reserve. The time interval between the initial clinic
attendance and invasive coronary angiography or
coronary revascularization procedure was recorded.
MEDICATIONS. The Scottish national community
drug-prescribing database of the Information Services
Division of the National Health Service (NHS) Scot-
land maintains a detailed record of all NHS pre-
scriptions dispensed in the community, which are
linked to individual patient identifiers. All of these
prescriptions are dispensed by community pharma-
cies, dispensing doctors, and a small number of
specialist appliance suppliers. Preventive medica-
tions were categorized into antiplatelet, statin, and
angiotensin-converting enzyme inhibition therapies.
We extracted information on which medications were
obtained and the timing of dispensing from the
pharmacist. The time interval between randomiza-
tion to the dispensing of the prescription was
determined.OUTCOMES. The Scottish national morbidity record
with linkage to the General Registers Office was used
to obtain information on the long-term outcomes of
the study including death, myocardial infarction (MI),
and cerebrovascular disease. This information also
was obtained from the Information Services Division
of NHS Scotland and, where appropriate, confirmed
with review of the electronic patient health records.
The inpatient and day-case national dataset collects
episode-level data across all hospitals in Scotland.
This includes discharge diagnostic codes using the
International Classification of Disease, 10th Revision,
system and operational codes using the Office of
Population Censuses and Surveys’ Classification of
Interventions and Procedures, as described previ-
ously (3). Categorization of cardiovascular events and
cause of death was adjudicated blinded to trial
allocation.
STATISTICAL ANALYSIS. Statistical analysis was
performed using SAS version 9.4 (SAS Institute, Cary,
North Carolina). Data were analyzed using Cox pro-
portional hazards regression and presented graphi-
cally using Kaplan-Meier plots. Logistic regression
models were used to compare the changes in pre-
scriptions between the 2 treatment arms. All analyses
were adjusted for center and minimization variables
excluding the baseline diagnosis. To examine
whether there was a change in the HR after 50 days, a
randomized treatment by time interaction term was
added in to the model of fatal and nonfatal MI. Cost
analyses were performed as detailed in the Online
Appendix. Analyses were post-hoc, and statistical
significance was defined as a 2-sided p < 0.05.
RESULTS
Of the 4,146 patients recruited into the study, 2,073
were assigned to standard care and 2,073 to standard
care plus CCTA. Participants were age 57  10 years
and had a body mass index of 30  6 kg/m2; 56%
(n ¼ 2,325) were male. Patient characteristics have
previously been described in detail (3) and patients
were followed for a median of 20 months (range 3 to
49 months).
CORONARY COMPUTED TOMOGRAPHY ANGIOGRAPHY.
Of those 2,073 patients assigned to standard care
plus CCTA, 1,778 (86%) underwent CCTA with the
remainder (n ¼ 295; 14%) defaulting or not comple-
ting the scan. The median interval between random-
ization and CCTA was 12 days (interquartile range
[IQR]: 7 to 18 days) (Figure 1). CCTA demonstrated
normal coronary arteries in 654 (37%), mild non-
obstructive (10% to 50% luminal stenosis) disease in
FIGURE 1 Timing of Noninvasive and Invasive Coronary Angiography
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Cumulative events from clinic consultation to the conduct of: (A) coronary computed
tomography angiography (CCTA) in patients receiving the trial intervention, (B) invasive
coronary angiography by trial allocation, and (C) new invasive coronary angiography
consequent on the CCTA findings. Hazard ratio: 1.06 (95% confidence interval: 0.92 to
1.22); p ¼ 0.451 for rates of invasive coronary angiography between CCTA þ standard care
and standard care alone. Orange line indicates CCTA þ standard care. Blue line indicates
standard care alone.
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1762372 (21%), intermediate nonobstructive (50% to 70%)
disease in 300 (17%), and obstructive (>70%) disease
in 452 (25%) participants. By 6 weeks, CCTA was
associated with a higher rate of cancellation (29 vs. 1;odds ratio [OR]: 30.94 [95% confidence interval (CI):
4.20 to 227.72]; p ¼ 0.0008) and the request of new
(94 vs. 8; OR: 12.85 [95% CI: 6.21 to 26.59]; p < 0.0001)
invasive coronary angiograms that were performed
74 days (IQR: 53 to 95 days) after clinic consultation
(Figure 1).
INVASIVE CORONARY ANGIOGRAPHY. Over the
total trial follow-up period, there were no differ-
ences in the number of invasive angiographic pro-
cedures (409 vs. 401; HR: 1.06 [95% CI: 0.92 to
1.22]; p ¼ 0.451) (Figure 1). However, invasive cor-
onary angiography was less likely to demonstrate
normal coronary arteries (20 vs. 56; HR: 0.39 [95% CI:
0.23 to 0.68]; p < 0.001) and more likely to
show obstructive coronary artery disease (283 vs.
230; HR: 1.29 [95% CI: 1.08 to 1.55]; p ¼ 0.005) in
patients assigned to CCTA. There was no difference
in the rates of nonobstructive coronary artery dis-
ease (97 vs. 107; HR: 1.01 [95% CI: 0.76 to 1.35];
p ¼ 0.926).
Overall, there was an apparent trend for more
coronary revascularization procedures (233 vs. 201;
HR: 1.20 [95% CI: 0.99 to 1.45]; p ¼ 0.061) to occur in
those allocated to CCTA. Coronary revascularization
(percutaneous coronary intervention or coronary
artery bypass grafting) was performed 76 days (IQR:
56 to 118 days) after clinic attendance.
PREVENTIVE MEDICATIONS. Compared with stan-
dard care, clinicians were more likely to recommend
cancellation (77 vs. 8; OR: 10.75 [95% CI: 5.51 to
22.42]; p < 0.001) and initiation (293 vs. 84; OR:
4.12 [95% CI: 3.19 to 5.33]; p < 0$001) of preventive
therapies after CCTA. This was attributable to the
changes in the diagnosis consequent on the CCTA
result (Online Table 1). New preventive therapies
were composed of antiplatelet (n ¼ 220 vs. 33;
HR: 12.17 [95% CI: 7.52 to 19.71]; p < 0.001), statin
(n ¼ 226 vs. 80; HR: 3.49 [95% CI: 2$63 to 4.62];
p < 0.001), and angiotensin-converting enzyme in-
hibition (n ¼ 19 vs. 1; HR: 10.73 [95% CI: 1$38 to
83.25]; p ¼ 0.0232) therapies. After clinic atten-
dance, these recommendations were generally im-
plemented (283 vs. 74; HR: 4.05 [95% CI: 3.13 to
5.23]; p < 0.001) and associated with the issuing of
347 new prescriptions at a median of 50 days (IQR:
36 to 66 days) for antiplatelet, 52 days (IQR: 37 to
66 days) for statins, and 48 days (IQR: 31 to
89 days) for angiotensin-converting enzyme inhibi-
tion therapies (Figure 2).
CLINICAL OUTCOMES. As anticipated, rates of MI
were highest in those with obstructive coronary
heart disease and were intermediate in those with
FIGURE 2 Timing of Initiation of New Preventive Therapies
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(hazard ratio: 12.17 [95% confidence interval: 7.52 to 19.71]; p < 0.0001) and (B) statin
therapy (hazard ratio: 3.49 [95% confidence interval: 2.63 to 4.42]; p < 0.0001),
according to trial allocation. Orange line indicates coronary computed tomography
angiography þ standard care. Blue line indicates standard care alone.
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1763nonobstructive disease (Online Figure 1). Compared
with standard care, the rates of fatal and nonfatal MI
appeared to be reduced in patients undergoing CCTA
(26 vs. 42; HR: 0.62 [95% CI: 0.38 to 1.01]; p ¼ 0.0527).
Although there was no statistically significant inter-
action between treatment and time (p ¼ 0.324), and
the results are on the basis of a small number of
events, there was an apparent separation of the event
curves several weeks after randomization (Figure 3A).
Given that changes in clinical events cannot be
attributable to the CCTA alone, we explored the
timing of treatment changes consequent on the CCTA
using the dispensing of preventive therapies. Prior to
the median time for the implementation of preven-
tive therapies (0 to 49 days), there were no differ-
ences in the rates of fatal and nonfatal MI according
to randomized trial allocation (9 vs. 8; HR: 1.09
[95% CI: 0.42 to 2.83]; p ¼ 0.8589). Analysis of events
at $50 days suggested a halving in the rate of fatal
and nonfatal MI (17 vs. 34; HR: 0$50 [95% CI: 0.28 to
0.88]; p ¼ 0.0202) (Figure 3, Online Table 2), and
nonfatal stroke, and nonfatal and fatal MI (22 vs. 40;
HR: 0.55 [95% CI: 0.33 to 0.91]; p ¼ 0.0245) in patients
allocated to CCTA compared with those assigned to
standard care.
HEALTH CARE COSTS. The cumulative mean cost of
treatment over 6 months was higher in the CCTA
group than for standard care alone: $1,900 versus
$1,438, difference $462 (95% CI: $303 to $621)
(Table 1). The total cost difference is attributable
to the direct costs of CCTA itself and was robust
for a range of assumptions that varied with the
mean unit cost of CCTA. There were no differences
in the costs attributed to outpatient, day-case, or
inpatient services, reflecting the broadly similar
rates of investigations and procedures following
randomization to either CCTA or standard care
alone. Overall, there were no differences in
the downstream costs: $89 (95% CI: $69 to $248)
(p ¼ 0.269).
DISCUSSION
We have previously reported that CCTA clarifies the
diagnosis, changes treatments and investigations,
and may improve outcomes in patients with sus-
pected angina pectoris due to coronary heart disease.
However, whether these changes in management
were appropriate and could be plausibly related to
apparent improvements in outcomes remained to be
established. Here, we have demonstrated that the
changes in the selection of patients for invasive cor-
onary angiography were appropriate, resulted in
markedly lower rates of normal coronary angiographyand a higher rate of obstructive coronary artery
disease, and apparently led to more coronary revas-
cularization procedures. In addition, the timing of the
subsequent changes in preventive therapies coin-
cided with the apparent divergence of event rates for
fatal and nonfatal MI. We conclude that the changes
in diagnosis consequent on CCTA led to appropriate
changes in the selection of patients for invasive cor-
onary angiography and the more effective imple-
mentation of preventive therapies, which were
FIGURE 3 Fatal and Nonfatal Myocardial Infarction With and Without the 50-Day
Implementation Delay
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1764associated with a halving in the subsequent rate of
fatal and nonfatal MI.
Studies addressing the diagnostic accuracy of
CCTA are well described (6,7), and the major strength
of CCTA relates to exclusion of coronary heart dis-
ease. Here, we have demonstrated that the addition
of CCTA to routine clinical assessment of patients
with suspected angina pectoris secondary to coronary
heart disease leads to a nearly 3-fold reduction in
the rates of normal invasive coronary angiography.These reductions in the rates of normal coronary
angiography were consistent with those observed in
the PROMISE (PROspective Multicenter Imaging
Study for Evaluation of chest pain) trial (8), although
the proportionate reductions were even greater in the
present study. Importantly, we also found that not
only did the rate of normal coronary arteries fall, but
also the rate of obstructive coronary artery disease
increased in those undergoing invasive coronary
angiography. This suggests better use of invasive
angiography, especially as the rate of coronary
revascularization was high in those for whom CCTA
had changed the initial diagnosis and suggested the
presence of obstructive disease. Given the potentially
greater hazards and costs of invasive angiography,
our findings indicate that CCTA is as an effective and
readily applicable gatekeeper for the conduct of
invasive coronary angiography with a view to coro-
nary revascularization in patients with suspected
angina pectoris due to coronary heart disease.
Models have suggested that CCTA can be used to
select asymptomatic individuals at higher risk of
cardiovascular events for preventive therapy (9,10).
Indeed, a recent substudy of the CONFIRM (COronary
computed tomography angiography evaluatioN For
clinical outcomes InteRnational Multicenter) registry
suggested that the baseline use of statin therapy was
associated with lower mortality in asymptomatic pa-
tients with nonobstructive or obstructive coronary
artery disease identified by CCTA, whereas mortality
was unaffected in those with normal coronary arteries
(11). In contrast, McEvoy et al. (12) reported that
although aspirin and statin therapy use was increased
in 1,000 asymptomatic patients who underwent CCTA
for the identification of coronary artery disease,
mortality was no different than in a referent control
group that had not undergone CCTA. For symptom-
atic patients with suspected coronary artery disease,
the presence and severity of coronary artery disease
identified on CCTA is associated with the increased
use of preventive therapies such as aspirin and statin
therapies (13,14) as well as lifestyle modification
(14,15). A single-center registry of 8,372 patients with
nonobstructive coronary artery disease identified by
CCTA also showed that statin therapy was associated
with lower mortality, but aspirin therapy was only
associated with lower mortality in high-risk patients
(16,17). However, all of these observational studies
have many potential biases, including case selection
bias and confounding by treatment allocation. Our
study avoids these biases through the conduct of a
randomized controlled trial of all patients attending
the cardiology clinic for suspected angina pectoris
due to coronary heart disease. Because the allocation
TABLE 1 Cumulative 6-Month Resource Use and Costs
Coronary Computed
Tomography Angiography
(n ¼ 2,073)
Standard Care
(n ¼ 2,073)
Difference
(95% Confidence
Intervals) p Value*
Investigation
Invasive coronary angiography 17.5 16.3 1.2 (1.0 to 3.5) 0.28
Coronary revascularization
Percutaneous coronary intervention 8.9 7.1 1.8 (0.4 to 4.0) 0.11
Coronary artery bypass graft surgery 1.9 1.8 0.1 (0.1 to 0.0) 0.73
Total hospital length of stay, days 0.3  0.8 0.3  0.8 0.0 (0.1 to 0.0) 0.86
Component costs, USD
Coronary computed tomography angiography 372  163 [416] 0  16 [0] 372 (363 to 378) <0.001
Outpatient services 219  655 [0] 192  584 [0] 27 (10 to 66) 0.16
Day-case services 890  1,196 [0] 827  1,189 [0] 63 (10 to 136) 0.09
Inpatient services 379  1,906 [0] 379  1,864 [0] 1 (113 to 116) 0.98
Medications 52  67 [0] 50  70 [0] 1 (3 to 6) 0.50
Total 6-month costs, USD $1,900  $2,642 [$552] $1,438  $2,581 [$86] $462 ($303 to $621) <0.001
Values are % or mean  SD [median], unless otherwise specified. *Student t test.
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1765of imaging was randomized, the subsequent down-
stream alterations in treatment can be attributable to
the imaging intervention. In addition, although
the SCOT-HEART trial event rates were relatively
modest, the rates of fatal and nonfatal MI in trial
participants were greater than those observed in
asymptomatic individuals (9,16) and similar to those
in symptomatic patients with stable disease (18,19).
Finally, the benefits of preventive therapies are
greatest in treatment naïve patients with new-onset
angina pectoris, especially given that the latter
is associated with a potentially more unstable
course and represents an intermediate-severity risk
group (1,20).
We collected data from the attending clinicians
6 weeks after the clinic consultation to ascertain the
recommended changes in management and treatment
of patients in both allocated groups. Compared with
standard care, there were marked differences in the
recommendations of how the patients were to be
managed and treated following CCTA (3). However,
were these changes implemented, and if so, when? We
explored both the implementation and the timing
of these changes using national electronic health re-
cords and prescribing data. This was a major strength
of our study and has not previously been employed in
other trials of this type. We were able to determine
the exact date of the dispensing of medications
to individual patients consequent on the attending
clinicians recommendations. We described the inev-
itable delay consequent on the time taken to under-
take the CCTA, the report to be issued, the attending
clinician to review and act on the report, the primary
care physician to implement the recommendation,and ultimately, for a prescription to be submitted and
medication dispensed to the patient. The median
time delay from clinic consultation to the dispensing
of medications was approximately 50 days for
aspirin, statin, and angiotensin-converting enzyme
inhibitor therapies.
There are currently no noninvasive imaging strate-
gies that have been shown to reduce cardiovascular
events in a randomized controlled trial. This is perhaps
not surprising, because there are multiple steps from
diagnosis to treatment to clinical events, and it is
challenging to demonstrate the effectiveness of an
imaging strategy on hard clinical outcomes (21). How-
ever, we have reported that the use of CCTA is associ-
ated with an apparent reduction in fatal and nonfatal
MI. Because the overall event rates were low and the
absolute number of events small, this has raised 2
specific questions: is this a real effect, and if so, what is
the mechanism? These new data help us to address
these questions. First, although there was no statisti-
cally significant interaction between time and the trial
intervention, the event curves did appear to overlap
before diverging after approximately 2 months. From
first principles, this is not surprising given that our
current data clearly demonstrate a time delay from
clinic consultation to CCTA conduct and implementa-
tion of new therapy. Second, an effect on outcome is
not plausible unless the CCTA has led to changes in
therapy. We therefore assessed event rates after the
median time point where preventive therapies had
been prescribed and issued to the patients (50 days)
(Central Illustration). This was a conservative estimate
given that one-half of patients will still have not
received changes in treatment and coronary
CENTRAL ILLUSTRATION Clinical Effect of CCTA in Suspected Angina Pectoris: Coronary Heart Disease
Death and Nonfatal Myocardial Infarction
Williams, M.C. et al. J Am Coll Cardiol. 2016;67(15):1759–68.
Post hoc landmark analysis at 50 days to account for the implementation and treatment delay consequent on the conduct, reporting, and communication of
the coronary computed tomography angiography (CCTA) findings. HR ¼ hazard ratio.
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1766revascularization procedures took considerably longer
to deliver. Despite this, we report a point estimate
suggesting a halving in the event rates for fatal and
nonfatal MI. Finally, we believe this reduction in
events is consistent with the anticipated effect size
attributable to initiation of preventive therapies
(18,19,22–24) together with potential benefits from
life-style modification and coronary revasculariza-
tion (25,26). Moreover, it is likely that the early re-
ductions in events will be attributable to antiplatelet
therapy (22,23), with later benefits potentially seen
with statin therapy (18,24) and coronary revascular-
ization procedures (25,26). Finally, the observed
halving of coronary heart disease events is also
consistent with our previous findings of improved
outcomes following the introduction of betterdiagnostic pathways in the setting of patients pre-
senting with suspected acute coronary syndrome
(27).
STUDY LIMITATIONS. The major limitation of the
present study is the modest number of events, albeit
in over 4,000 patients. This reflects the fact that the
majority of subjects had no or minimal coronary
artery disease and therefore were not at risk. The
coronary heart disease (fatal and nonfatal MI) event
rate in all patients receiving standard care alone was
2.2% over 20 months. However, the actual rate in
those who had significant coronary artery disease was
much higher (Online Figure 1) and is consistent with
event rates of patients with proven coronary heart
disease (18,19). We intend to continue follow-up for a
PERSPECTIVES
COMPETENCY IN PATIENT CARE AND PROCEDURAL
SKILLS: In patients with symptomatic coronary disease, the
results of CCTA can guide referral for invasive angiography and
revascularization and reduce the risk of MI.
TRANSLATIONAL OUTLOOK: Further studies are needed
to determine whether guiding clinical management of patients
with ischemic heart disease by initial coronary CCTA improves
long-term outcomes.
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1767median of 5 years to allow the accrual of more events
that will enable more precise estimates of benefit and
facilitate the further exploration of our secondary
endpoints.
CONCLUSIONS
We have demonstrated that CCTA facilitates the more
appropriate and effective selection of invasive coro-
nary angiography for patients with suspected angina
due to coronary heart disease. CCTA also changed the
downstream prescribing of preventive therapies
and the application of coronary revascularization
procedures that were associated with an apparent
halving in the rates of fatal and nonfatal MI.
Arguably, this is the first time that a noninvasive
diagnostic test for coronary heart disease has
demonstrated a benefit in hard clinical outcomes
through better targeted investigations and treat-
ments in patients presenting with suspected angina
pectoris due to coronary heart disease.REPRINT REQUESTS AND CORRESPONDENCE: Dr.
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